Industry

In the EPIC-SR study of PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets), the novel primary endpoint of self-reported, sustained alleviation of all symptoms for four consecutive days was not met, as previously reported Data from standard-risk patients, both vaccinated and unvaccinated, while not all statistically significant, are supportive of efficacy data observed in EPIC-HR study … [Read more…]

DANVERS, Mass.–(BUSINESS WIRE)–Abiomed, Inc. (NASDAQ: ABMD) today announced that it will host an investor call on the heart failure opportunity with the Impella 5.5 and future Impella BTR heart pumps on June 24, 2022 from 2:30 p.m. – 3:30 p.m. ET. The event will include presentations from heart failure specialists, Dr. David D’Alessandro, Surgical Director, … [Read more…]

Update on Business Segments and PURE’s SDC-Based Antimicrobial Solutions RANCHO CUCAMONGA, Calif.–(BUSINESS WIRE)–PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal third quarter and nine-month period ended April 30, 2022. Q3: Summary of Results of Operations Net product sales for the fiscal … [Read more…]

LA JOLLA, Calif.–(BUSINESS WIRE)–DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that its chief medical officer, Dr. Loren Clarke, will present study data illustrating how genomic technology can enhance melanoma detection and improve patient care at America’s Health Insurance Plans (AHIP) … [Read more…]

Human Immunology Biosciences (HIBio) is a biotechnology company focused on developing precision medicines for autoimmune and inflammatory diseases, backed by ARCH Venture Partners and Monograph Capital HIBio obtains exclusive worldwide rights, with the exception of Greater China for felzartamab and Greater China and South Korea for MOR210 MorphoSys will receive a 15% equity stake in … [Read more…]

Immersive experience for privacy and security programs like HIPAA ATLANTA–(BUSINESS WIRE)–#BlackTalonSecurity–Information privacy and security has increased in significance for companies and organizations of all sizes. However, as the toll information losses and cyberattacks take on companies are fully realized, the stakes are higher than ever for those responsible for protecting critical data and infrastructure. To … [Read more…]

WASHINGTON–(BUSINESS WIRE)–Gallup’s latest State of the Global Workplace Report finds that, despite more than two years of the pandemic, U.S. and Canadian workers seemed to rebound in 2021. Employees reported higher life evaluations than the previous year and declines across several negative emotions. In 2021, 33% of U.S. and Canadian employees were engaged at work … [Read more…]

CHICAGO–(BUSINESS WIRE)–MERGE, a premium storytelling and technology company, announced today that it has been named to the MM&M 2022 Agency 100. MERGE advanced four spots to number 15 in 2022. The Agency 100 recognizes the top agencies, from boutique to multinational, in medical marketing and communications, putting MERGE among the industry elite. Nominees are selected … [Read more…]

First presentation of initial LuMIERE Phase 1 data demonstrated a manageable safety profile with preliminary evidence of activity Nine patients treated to date with 177Lu-FAP-2286 up to 5.5 GBq/dose No serious adverse events, treatment discontinuations, deaths or dose-limiting toxicity events related to 177Lu-FAP-2286 observed Confirmed partial response in one patient who completed six administrations of … [Read more…]

Grant will support Company’s first US-based clinical trial, to be conducted at Baylor College of Medicine New Immunopheresis® therapeutic molecular ligand-capture platform is designed to activate endogenous antitumor pathways by removing factors shed by cancer cells that suppress immune response and promote cancer growth The Company’s fourth clinical trial seeks to provide important safety, efficacy, … [Read more…]